A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet‐induced obese rats
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Aim: To investigate the effects of acute and chronic administration of a novel oral formulation of salmon calcitonin (sCT) on glycaemic control, glucose homeostasis and body weight regulation in diet‐induced obese (DIO) rats—an animal model of obesity‐related insulin resistance and type 2 diabetes. Methods: DIO rats were acutely given a single dose of oral sCT (0.5 and 2 mg/kg), its oral vehicle N ‐(5‐chlorosalicyloyl)‐8‐aminocaprylic acid (5‐CNAC) or injectable sCT (5 and 10 µg/kg) (n = 8), followed by oral glucose tolerance test (OGTT). Other DIO rats were chronic treated twice daily with oral vehicle 5‐CNAC (n = 6), oral sCT (0.5 and 2 mg/kg) or injectable sCT (10 µg/kg) (n = 8). Fasting and postprandial glucose and pancreatic hormones, body weight and insulin sensitivity were assessed. Results: A single dose of oral sCT acutely reduced glucose and insulin area under the curve during OGTT by approximately 65 and 85%, respectively, compared with vehicle (p < 0.001). Chronic treatment with oral sCT significantly reduced both fasting and postprandial glucose and insulin levels by approximately 1.5 mM and 65%, respectively, compared with vehicle. Oral sCT concomitantly improved insulin sensitivity (homeostatic model assessment, HOMA). In contrast, injectable sCT resembling higher systemic exposure did not improve glycaemic control, either acutely or during chronic treatment. Furthermore, both oral and injectable sCT reduced body weight by 15% compared with vehicle (p < 0.05). Conclusion: A novel oral form of sCT showed antidiabetic effects in DIO rats by improving glycaemic control, glucose homeostasis, insulin sensitivity and body weight.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518 · cited 2×
“GIP, GLP-2) [33] and glucagonostatic properties (e.”
Hypoglycaemia in Type 2 diabetes
Amiel, S. A., Dixon, T., Mann, R., & Jameson, K. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02341.x · Cited by 472
Gastric emptying in diabetes: clinical significance and treatment
Horowitz, M., O’Donovan, D., Jones, K. L., Feinle, C., Rayner, C. K., & Samsom, M. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00658.x · Cited by 308 · cited 1×
“During early stages of diabetes, there is accelerated gastric emptying, which may itself increase postprandial glucose levels, and experimental studies have shown that changes in gastric emptying markedly influence postprandial glucose excursions [25].”
BackgroundEffect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes
Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., Wang, Y., Burns, C., Lush, C., Weyer, C., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1732-4 · Cited by 205 · cited 1×
“Furthermore, in DIO rats and obese type 2 diabetic patients, respectively, amylin and pramlintide stimulates weight loss by inducing satiety and reducing food intake [8,9], thus counteracting the weight-enhancing action of insulin.”
BackgroundOn the physiology of GIP and GLP-1
Holst, J. J. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826158 · Cited by 189 · cited 1×
“GLP-1 and glucosedependent insulinotropic peptide (GIP)], thereby further influencing intestinal glucose absorption [29] and postprandial glucose levels, although this awaits further investigations.”
BackgroundReview of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes
Ryan, G., Jobe, L., & Briscoe, T. (2008) · Drug Design, Development and Therapy · doi:10.2147/dddt.s3225 · Cited by 98
Ahr�n, B., & Larsson, H. (2001) · Diabetologia · doi:10.1007/s001250100003 · Cited by 95 · cited 1×
“Furthermore, lack of glucagon suppression in response to oral glucose or carbohydrate ingestion markedly increases hepatic glucose production and thereby contributes significantly to postprandial hyperglycaemia in obesity and diabetes [26].”
BackgroundSondergaard, B., Oestergaard, S., Christiansen, C., Tankó, L. B., & Karsdal, M. A. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22797 · Cited by 65 · cited 2×
“The high oral doses of sCT (2 mg/kg) were similar to that used in other animal studies investigating osteoarthritis [17].”
BackgroundMethodSelf-citation
Cited by
Amylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
Prolonged Calcitonin Receptor Signaling by Salmon, but Not Human Calcitonin, Reveals Ligand Bias
Andreassen, K. V., Hjuler, S. T., Furness, S. G., Sexton, P. M., Christopoulos, A., Nosjean, O., Karsdal, M. A., & Henriksen, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092042 · Cited by 89
Self-citationZakariassen, H. L., John, L. M., & Lutz, T. A. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13427 · Cited by 37
Larsen, A. T., Gydesen, S., Sonne, N., Karsdal, M. A., & Henriksen, K. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00678-2 · Cited by 33
Self-citation
Metadata
- Authors
- Feigh, M., Henriksen, K., Andreassen, K. V., Hansen, C., Henriksen, J. E., Beck‐Nielsen, H., Christiansen, C., & Karsdal, M. A.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2011-09-06
- Volume
- 13
- Issue
- 10
- Pages
- 911-920
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2070235880
- Cited by
- 45
- References
- 9
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet‐induced obese rats. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01425.x
- The paper
- Feigh, M., Henriksen, K., Andreassen, K. V., Hansen, C., Henriksen, J. E., Beck‐Nielsen, H., Christiansen, C., & Karsdal, M. A. (2011). A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet‐induced obese rats. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01425.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.